GRI Bio, Inc.
The research page contains a warning that has not been mapped to a supported model interpretation. The company research remains available, but the complete score is withheld until the warning is reviewed.
GRI · Price history
Price at last available close
$1.58
−$0.52 (-24.76%) 1M
2026-10-27
Tap or drag sideways to inspect a price. Use two fingers to compare automatically. Release to scroll. Use Shift + arrow keys to compare with a keyboard.
Company & revenue
About GRI Bio, Inc.
Primary reporting period: 2025-12-31 · Research updated Oct 13, 2026. A research update is not a new financial filing.
Who they are
GRI Bio, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing therapies that target diseases leading to inflammatory, fibrotic, and autoimmune disorders in the United States. Its lead product candidate is GRI-0621, an oral inhibitor of type 1 Natural Killer T cells, which is in phase IIa clinical trial for the treatment of severe fibrotic lung diseases, such as idiopathic pulmonary fibrosis. The company’s portfolio also includes GRI-0803, a novel oral agonist of type 2 Natural Killer T cells that is in preclinical development for the treatment of autoimmune disorders; a proprietary library of 500+ compounds; and GRI-0124 and GRI-0729 for balance inflammatory immune responses.
How they make money
GRI Bio is a clinical-stage biopharmaceutical company that does not currently generate revenue from product sales. It funds its operations primarily through the issuance of equity and debt securities to support the research and development of its proprietary pipeline of immune cell modulators.
Products & services
The company is developing a pipeline of therapies targeting inflammatory, fibrotic, and autoimmune diseases, including its lead candidate GRI-0621 and preclinical candidates GRI-0803, GRI-0124, and GRI-0729.
Brands & revenue mix
No separate brand or brand-level revenue disclosure was confirmed in the reviewed sources. This does not mean the company has no brands.
Product / operating segments
No reconciled product or operating-segment revenue breakdown is available for the current research period. Company-wide revenue remains separate from segment disclosure.
Geographic revenue
No reconciled geographic revenue breakdown was confirmed for the current research period.
Customer types
- Healthcare providers and patients (potential future market)Source
Customer concentration
No quantified customer-concentration disclosure is available in the current saved research.
Suppliers, materials & equipment
- Contract Research Organizations (CROs) — The company relies on third-party contract research organizations to conduct its preclinical and clinical studies; specific supplier names are not disclosed.Source
Competitors
- Biopharmaceutical companies — The company competes with various established pharmaceutical and biotechnology companies that are developing therapies for inflammatory, fibrotic, and autoimmune diseases.Source
Sources
Company-specific research
Questions worth answering for GRI
These questions are generated from this company's current financial and score data so the page adds context instead of treating the headline score as a stand-alone conclusion.
- •How long can GRI fund negative free cash flow using its current cash position before it may need more debt or new shares?
- •How is GRI likely to use its cash advantage: reinvestment, acquisitions, debt reduction, dividends or buybacks?
- •What specifically needs to improve for GRI to reach sustainable profitability?
- •What future growth or profitability would be needed to justify GRI's current valuation?
- •What does the current fundamental change risk warning mean for the reliability or interpretation of GRI's score?
Essential Investment Snapshot
Market Cap
$3.5M
P/E Ratio
-0.0
EPS
$-43.70
52-Week High
$64.12
52-Week Low
$1.36
Beta
-0.66
Shares Outstanding
2.2M
Total Debt
$44K
Dividend
No current dividend
Liquidation Value / Share
$4.70
Momentum & Volatility Signals
Two different market-behavior signals. Momentum measures direction and trend strength. Volatility measures how large and unstable the price moves are, regardless of direction.
Weakening momentum
Elevated movement
A high momentum score means price has been trending upward with confirming short- and medium-term strength. A low score means downward or weakening momentum.
A high volatility score means larger, less stable price swings. It can happen while a stock is rising or falling, so high volatility is not automatically bullish or bearish.
Important: the volatility score above is based on realized price volatility. Implied volatility (IV) comes from options prices and represents the market's expected future movement. Wall Street Score will keep IV separate and will only display it when a verified options-chain feed is available.
Notices for GRI
Detected from reported data — verify before acting.Dividend history reported
Dividend payments are recorded. Review the dates and regular/special classification below; past payments do not guarantee future dividends.
Historical repurchase activity
Reported cash flows or share-count measures indicate past repurchase activity. This does not verify an active buyback authorization or future purchases.
Community Sentiment
0 active · 0 total callsNo personal call yet on GRI.
Potential upside factors
- +Growth opportunities may come from revenue expansion, margin improvement, new products, market-share gains, and stronger cash flow.
- +Proprietary library of over 500 compounds.
- +Focus on novel NKT cell modulation.
Potential downside factors
- −Key risks may include competition, margin pressure, debt levels, valuation risk, and changes in demand within the Biotechnology industry.
- −History of operating losses and expectation of future losses.
- −Need for additional capital to fund operations and clinical trials.
- −Dependence on third-party clinical trial providers.
These research factors come from saved company research and financial data, not community votes. They are starting points to verify against filings, not buy or sell recommendations.
Create a free account to make a call.
Scores
Click any score for full breakdownWas this stock page easy to understand?
One click helps us improve the research experience. This is not tied to an investment decision.
Score Changes
Score changes will appear once more historical records are available.
Price vs. Value
Valuation unavailableCurrent Price
$1.58
Model Intrinsic Value
—
Difference
—
Margin of Safety
—
Intrinsic value is not currently available for this stock, so valuation can't be calculated.
Financial Charts
Revenue
Additional Metrics
Operating Cash Flow
Total Debt
Total Assets
Net Margin %
Free includes 3 annual periods plus available TTM; Premium includes up to 10 annual periods. History depends on available company filings. Swipe the table horizontally to see older periods. A dash means unavailable, not zero.
| Line Item | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 | ···· | ···· | ···· | ···· | ···· |
| Cost of Revenue | $1K | $0.00 | $0.00 | $0.00 | ···· | ···· | ···· | ···· | ···· |
| Gross Profit | -$1K | $0.00 | $0.00 | $0.00 | ···· | ···· | ···· | ···· | ···· |
| Research & Development | $2.8M | $6.8M | $3.8M | $3.2M | ···· | ···· | ···· | ···· | ···· |
| SG&A Expenses | $5.6M | $5.2M | $4.5M | $8.2M | ···· | ···· | ···· | ···· | ···· |
| Operating Expenses | $8.3M | $12.0M | $8.2M | $11.4M | ···· | ···· | ···· | ···· | ···· |
| EBITDA | -$8.3M | -$12.0M | -$8.2M | -$11.0M | ···· | ···· | ···· | ···· | ···· |
| Operating Income | -$8.3M | -$12.0M | -$8.2M | -$11.4M | ···· | ···· | ···· | ···· | ···· |
| Interest Expense | $0.00 | $0.00 | $0.00 | $2.1M | ···· | ···· | ···· | ···· | ···· |
| Income Before Tax | -$8.3M | -$12.0M | -$8.2M | -$13.0M | ···· | ···· | ···· | ···· | ···· |
| Income Tax Expense | $0.00 | $0.00 | $0.00 | $0.00 | ···· | ···· | ···· | ···· | ···· |
| Net Income | -$8.3M | -$12.0M | -$8.2M | -$13.0M | ···· | ···· | ···· | ···· | ···· |
| Basic EPS | $-9.47 | $-121.80 | $0.33 | $-140450.24 | ···· | ···· | ···· | ···· | ···· |
| Basic Shares | 1.80M | 98.2K | 4.90M | 1.6K | ···· | ···· | ···· | ···· | ···· |
| Diluted Shares | 1.80M | 98.2K | 4.92M | 1.6K | ···· | ···· | ···· | ···· | ···· |
Earnings Summary
Revenue
$0
Estimate unavailable.
Revenue Beat/Miss
Not available (no estimate stored)
EPS
-$0.91
Estimate unavailable.
EPS Beat/Miss
Not available (no estimate stored)
Debt Change
-54.2%
Cash Change
+113.7%
Margin Change
Not available
Debt and cash show percentage changes versus the comparison period; margin shows the change in percentage points (pp). These are company-wide changes, not per-share amounts.
Financial Changes Since Prior Period
What Improved
- Cash position grew
- Debt reduced
Potential Score Impact
Positive indicators included cash levels, debt levels. Pressure indicators included EPS growth. These factors may support or pressure the Revenue, Management, Financial, and Debt categories; this summary does not claim that the stored scores changed.
Stored Earnings Analysis
EPS declined 97.5%. Cash increased 113.7%. Total debt declined 54.2%.
Earnings-Call Transcript
Earnings-call transcript analysis is not currently available.
These results may influence future scores when the next evaluation is completed.
Insider Activity
Guru / Smart Money
Guru Score
Smart Money
Number of Gurus
Total Guru Value
Avg Portfolio Weight
Largest Holder
Largest Holder %
New Positions
Increased Positions
Reduced Positions
Exited Positions
Net Guru Sentiment
Short Interest
Dividend History
Log in to view dividend history.
Conservative Projected Values
3 Years
$———.——
5 Years
$———.——
10 Years
$———.——
Conservative Projection Rate
——%
Conservative Projected Values — price projections derived from actual 10-year adjusted historical returns, conservatively adjusted and capped at 8% annually. These are distinct from the Outperformance Model Score and WallStreetScore.
Conservative Projected Values
Premium unlocks the 3-year, 5-year, and 10-year conservative projected values with full calculation breakdowns based on actual historical returns.
Start 7-Day Free TrialHistorical Outperformance Record
Premium includes stored forecasts and any available evaluated results. Completed results, win rates and calibrated probabilities are shown only when supported records exist; access does not create historical outcomes.
Start 7-Day Free TrialHistorical Trends
4 historical recordsHistorical Score Chart
3 of 4 records shownWall Street Score
Debt Score
Revenue Score
Asset Score
Capital Score
Management Score
Moat Score
Valuation Score
Buffett Score
Intrinsic Value
Value Reference
Margin of Safety %
Related Companies
BiotechnologyNews
GRI Bio to Highlight Immune Modulation and Phase 2a Development Insights in IPF at the 10th IPF Summit
GRI Bio, Inc. (GRI) Upgraded to Buy: What Does It Mean for the Stock?
UPDATED: Watching GRI Bio; Zacks Investment Research Upgrades Stock To Buy
GRI Bio Presents New Phase 2a Data at ERS 2026 Defining GRI-0621's Mechanism of Action in IPF Across Nine Mechanistic Pillars
Rumor Mill · GRI
Corporate developments & opportunities
No reviewed developments match this filter.
Evidence credibility is not a forecast of stock performance. Rumor Mill is separate from the WSS score.
Related Stock Research
Continue researching this company with related Wall Street Score rankings and investing guides.
Score Alerts
Premium unlocks alerts when a score rises, falls, or reaches your target price.
Start 7-Day Free TrialPortfolio Score
Premium unlocks portfolio scoring, strongest and weakest holdings, and overall margin of safety.
Start 7-Day Free Trial